These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803 [TBL] [Abstract][Full Text] [Related]
4. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling. Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436 [TBL] [Abstract][Full Text] [Related]
5. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994 [TBL] [Abstract][Full Text] [Related]
6. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508 [TBL] [Abstract][Full Text] [Related]
7. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer. Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
12. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532 [TBL] [Abstract][Full Text] [Related]
13. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
14. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Lockwood WW; Zejnullahu K; Bradner JE; Varmus H Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625 [TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878 [TBL] [Abstract][Full Text] [Related]
17. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272 [TBL] [Abstract][Full Text] [Related]
18. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related]
20. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]